PAUL BOWERS: Open Payments
NPI 1386682862 · POCATELLO, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$626 in 36 payments from 13 companies in 2025. Trend: 2023 $722 · 2024 $763 · 2025 $626
Food & beverage: $626
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $171 |
| Vanda Pharmaceuticals Inc. | 4 | $75 |
| Novo Nordisk Inc | 4 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $64 |
| Amgen Inc. | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 3 | $49 |
| Astellas Pharma US Inc | 1 | $34 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
Products named: VRAYLAR, FANAPT, QULIPTA, GVOKE HYPOPEN, EVENITY, VOQUEZNA, Ozempic, Veozah.
Industry payments across ID — which companies pay providers there.
